风险提示：项目进度不及预期，产品及原料价格大幅波动，贸易摩擦风险。 美国植物胶囊反倾销影响有限，产能出海第二成长曲线可期。保健品行业是目前植物胶囊的主要下游行 业，美国、英国和欧盟国家是传统的保健品消费市场。2025 年5 月23 日，美国商务部宣布对进口自中 国、巴西、印度和越南的硬质空心胶囊作出反倾销初裁，初步裁定中国生产商/出口商的倾销率为5.40% －172.24%，面对不合理的贸易壁垒，公司积极应对并布局产能出海。据公告，公司拟通过自有资金或 外部融资方式在美国投资建设200 亿粒/年植物胶囊项目，计划投资金额不超过人民币5 亿元，截至 25Q2，公司美国植物胶囊项目在建工程进度为31.9%。随着公司美国植物胶囊工厂落地，公司产能直供 主要消费地区，区位优势明显，叠加纤维素醚-植物胶囊的一体化成本优势，中长期看公司第二成长曲 线可期。 投资建议：预计2025-2027 年公司归母净利润为2.21/3.39/4.27 亿元,首次覆盖，"推荐"评级。 事件：公司发布2025 年半年报，报告期内公司实现营收9.72 亿元，同比+4%，实现归母净利润1.13 亿 元，同比-9%；25Q2 公司实现营收5.0 ...

每经AI快讯，山东赫达（SZ 002810，收盘价：13.71元）8月25日晚间发布公告称，公司第九届第二十 五次董事会会议于2025年8月22日在公司会议室召开。会议审议了《关于 <公司2025年半年度报告及摘 要> 的议案》等文件。 2025年1至6月份，山东赫达的营业收入构成为：纤维素醚占比72.98%，植物胶囊占比21.1%，贸易化工 产品-其他占比3.86%，石墨类化工设备占比1.9%，其他业务占比0.16%。 （记者 张喜威） 截至发稿，山东赫达市值为48亿元。 每经头条（nbdtoutiao）——A股成交连续8天破2万亿元，券商招聘也来了！行业巨头秋招"求才"，25个 岗位都有什么特点？ ...

Core Viewpoint - The company, Shandong Heda Group Co., Ltd., is changing part of the fundraising purpose from the issuance of convertible bonds to permanently supplement working capital, which is deemed necessary for its operational needs and will not adversely affect other investment projects [1][5][9]. Fundraising Overview - The company was approved to issue 6 million convertible bonds with a total fundraising amount of 600 million RMB, netting approximately 592.75 million RMB after deducting issuance costs [1][2]. - As of June 30, 2025, the company has utilized approximately 457.47 million RMB of the raised funds, leaving a balance of about 135.76 million RMB [2][4]. Fund Usage Details - The remaining funds include 120 million RMB that was temporarily used to supplement working capital and has since been returned [2][4]. - The company plans to terminate the investment project for "Hershey's annual production of 15 billion plant capsules and intelligent three-dimensional warehouse upgrade project," which was initially planned for an investment of 181.68 million RMB [5][6]. Reasons for Fund Usage Change - The decision to halt the aforementioned project is influenced by changes in the international situation and market environment, which have affected the project's feasibility [5][6]. - The remaining funds will be used for daily operations and business development, enhancing the efficiency of fund usage and alleviating financial pressure [5][8]. Impact of Fund Usage Change - The change in fund usage is considered a prudent adjustment that aligns with the company's operational needs and will not negatively impact other investment projects [5][8]. - The company aims to optimize resource allocation and reduce financial costs, thereby improving operational efficiency and safeguarding the interests of the company and its investors [8][9]. Approval Process - The board of directors and the supervisory board have approved the change in fund usage, which will be submitted for further approval at the shareholders' meeting and the bondholders' meeting [8][9].

Core Viewpoint - Shandong Heda Group Co., Ltd. maintains a stable credit rating of AA- for both its corporate entity and its convertible bonds, indicating strong financial health and operational stability [1][4][5]. Company Overview - Shandong Heda primarily engages in the production of cellulose ether and plant capsules, maintaining certain technological and cost advantages [5][6]. - The company has been recognized as a "Little Giant" enterprise by the Ministry of Industry and Information Technology, reflecting its specialized and innovative capabilities [6][17]. Financial Performance - The revenue from cellulose ether has increased due to higher sales in pharmaceuticals, food, and industrial applications, while plant capsule revenue has also grown due to increased inventory for overseas sales [5][6]. - The gross margin for cellulose ether has decreased significantly, down 6.38 percentage points year-on-year to 19.13%, attributed to reduced demand in the domestic construction sector and intensified market competition [7][16]. - The gross margin for plant capsules has improved due to a decrease in fixed cost amortization following increased production [5][6]. Debt and Financial Health - As of the end of 2024, the company had total debts of 11.10 billion yuan, with a debt-to-capitalization ratio of 33.43%, indicating a light debt burden [7][9]. - The company’s short-term debt coverage is strong, with cash and cash equivalents significantly exceeding short-term liabilities [7][9]. - The overall financial risk remains low, with strong debt repayment capabilities supported by robust cash flow metrics [5][6]. Market and Industry Analysis - The cellulose ether market is expected to face continued competition, particularly in the construction sector, which is heavily influenced by the real estate market's performance [14][15]. - The global cellulose ether market is projected to grow from 5.229 billion USD in 2024 to 6.719 billion USD by 2031, indicating potential growth opportunities despite current competitive pressures [14][15]. - The company has established strong relationships with major clients in the construction and pharmaceutical sectors, enhancing its market position [17][18]. Regulatory and External Factors - The company is currently facing uncertainties due to the U.S. "double anti" investigation, which could significantly impact its plant capsule business in the U.S. market [5][6]. - The overall economic environment is characterized by a stable macroeconomic policy aimed at maintaining growth and supporting domestic demand, which may benefit the company in the long run [13][14].

Core Points - Shandong Heda Group Co., Ltd. has issued convertible bonds totaling 600,000 units with a face value of RMB 100 each, raising a total of RMB 60 million [3][14] - The bonds will be traded on the Shenzhen Stock Exchange under the name "Heda Convertible Bonds" starting from July 19, 2023 [3][4] - The initial conversion price for the bonds is set at RMB 17.40 per share, with specific conditions for adjustments based on stock performance [6][8] Section 1: Bond Overview - The bond issuance was approved by the company's board and shareholders in April and May 2022 [2] - The total amount raised after deducting issuance costs is RMB 59.275 million [3][14] - The bonds have a six-year term, with interest rates increasing from 0.20% in the first year to 3.00% in the sixth year [4][5] Section 2: Financial Performance - For the fiscal year ending December 31, 2024, the company reported total assets of RMB 4.146 billion, a 5.49% increase from the previous year [15] - The company's revenue for 2024 was RMB 1.956 billion, reflecting a 25.72% year-over-year growth [15] - The net profit attributable to shareholders decreased by 10.90% to RMB 193.495 million [15] Section 3: Fund Utilization - The funds raised will be used for the "Hershey Annual Production of 15 Billion Plant Capsules and Smart Warehouse Upgrade Project," with a total investment of RMB 1.227 billion [14] - The company has established a dedicated account for managing the raised funds, ensuring compliance with regulatory requirements [14][15] - As of December 31, 2024, the company had utilized RMB 454.304 million of the raised funds [15]

Report Summary 1. Report Industry Investment Rating - No information provided on the industry investment rating in the given content. 2. Core Viewpoints - The company's cellulose ether exports in May 2025 were in good condition, and the current price is basically stable without significant fluctuations [26][27][28]. - The US plant construction is in progress, and the company will disclose the progress according to regulatory requirements [24][25]. - The US factory only plans to build a plant - based capsule production line, and cellulose ether will be sourced through a combination of domestic imports and US procurement [31]. - The company's repurchased shares are for converting convertible corporate bonds, and it will choose an appropriate time to implement the repurchase plan after completing the approval procedures [30]. 3. Summary by Directory 3.1. Research Basic Situation - The research object is Shandong Hedda, belonging to the chemical products industry. The reception time was May 15, 2025, and the company's reception staff included the chairman, board secretary, financial director, and securities affairs representative [17]. 3.2. Detailed Research Institutions - The reception objects include investors' online questions and others [20]. 3.3. Research Institution Proportion - No information provided on the research institution proportion in the given content. 3.4. Main Content Data - **US Plant Construction**: It is in progress, and the company will disclose the progress as required. The US factory only plans a plant - based capsule production line, and cellulose ether will be sourced from domestic imports and US procurement [24][25][31]. - **Cellulose Ether**: Exports in May 2025 were good, and the current price is stable [26][27][28]. - **2025 Performance**: Details of the 2025 business plan can be found in the 2024 annual report [29]. - **Inventory Accounting**: The inventory of plant - based capsules reserved in the US warehouse is recorded under accounts receivable in the company's statements, and relevant revenues and costs have been offset [29]. - **Share Repurchase**: The repurchased shares are for convertible corporate bonds. After completing the approval procedures on May 14, 2025, the company will choose an appropriate time to implement the plan [30].

Group 1: Company Operations - The construction of the factory in the United States is currently in progress, with updates to be disclosed according to regulatory requirements [3] - The company reported good export performance for cellulose ether in May 2025 [4] - The price of cellulose ether has remained stable in 2025, with no significant fluctuations observed [5][6] Group 2: Financial and Strategic Plans - The company's 2025 performance is expected to grow, with detailed plans available in the 2024 annual report [7] - The strategy to address U.S. trade tariffs includes reserving 4 to 6 months' worth of plant-based capsules in the U.S. warehouse, classified as accounts receivable in financial statements [7] - The purpose of the share buyback is to convert shares into convertible bonds, with plans to implement the buyback at an appropriate time following regulatory approval [7] Group 3: Future Projections and Risks - The U.S. factory will only produce plant-based capsules, with cellulose ether sourced from domestic imports, which may still face high tariff risks [8]

Group 1: Company Overview - Recently, a well-known private equity firm, Xiangju Capital, conducted research on a listed company, Shanhe Pharmaceutical Auxiliary [1] - Shanhe Pharmaceutical Auxiliary expects a 22% growth in sales revenue for cellulose products in 2024, with a slight decline in overall prices [1] - The company anticipates stable prices in 2025 and strong demand for its products [1] Group 2: Financial Performance - Last year's gross margin slightly decreased, but there is potential for improvement this year [1] - The capacity utilization rate for four main products in the fundraising projects is between 60% and 70% [1] - The company expects significant growth in the sales of hard fumaric acid sodium in 2024, with over 100 domestic customers already using the product [1] Group 3: Market Dynamics - The auxiliary materials industry has vast potential, with many categories and significant room for import substitution, accelerated by the China-US trade war [1] - The new drug production quality management regulations will be implemented on January 1, 2026, which is expected to accelerate industry consolidation, benefiting leading companies [1] - The demand for plant capsules is strong, with good order prospects in the next six months, and there is potential for domestic gelatin capsules to be replaced [1] Group 4: International Business - The increase in tariffs by the US has not yet affected exports, as the export volume to the US is relatively small, and some products fall within the tariff exemption range [1] - Overseas business is expected to maintain rapid growth, although the gross margin is slightly lower due to fewer differentiated products being sold abroad [1]